BeiGene's success demonstrates a new model for biotech growth. It started in China and expanded globally, but critically maintains China as a core hub for innovation. This challenges the traditional view that biotech innovation flows primarily from the West and must be built from a US headquarters.
Related Insights
China has developed a first-rate biotech effort, enabling U.S. firms to buy or license preclinical assets more efficiently than building them domestically. This creates an arbitrage opportunity, leveraging China's R&D capabilities while relying on U.S. expertise and capital for global commercialization.
Based on experience with BeiGene's board, the CEO identifies the speed of implementing ideas and running multiple experiments in parallel as a major strength of Chinese biotech. This, combined with a vast pool of scientific talent, positions China as a formidable force in global innovation.
In stark contrast to the US, Chinese investors are accelerating funding for early-stage cell and gene therapies, which now account for 29% of seed/Series A rounds. These firms are specifically backing technologies like NK cell therapies, which have fallen out of favor in the West, creating a divergent global innovation strategy.
Contrary to lingering Western perceptions, the idea that data from Chinese biotechs is poor or that the country doesn't produce real innovation is outdated and incorrect. China's life sciences sector is now increasingly sophisticated and innovative, fueled by significant government investment, making it a critical global player that cannot be underestimated.
The cell therapy Carvykti, now a multi-billion dollar product for J&J, originated from Legend Biotech in China. When initial data showing a spectacular 100% response rate was presented at ASCO in 2017, it was met with widespread skepticism. This highlights how groundbreaking innovation can emerge from unexpected regions and be initially overlooked by the established scientific community.
China is no longer just a low-cost manufacturing hub for biotech. It has become an innovation leader, leveraging regulatory advantages like investigator-initiated trials to gain a significant speed advantage in cutting-edge areas like cell and gene therapy. This shifts the competitive landscape from cost to a race for speed and novel science.
China's ability to accelerate biotech development stems from faster patient recruitment for clinical trials. With a large, treatment-naive patient population willing to participate in studies, early-stage oncology trials can be completed in about half the time it takes in the US. This provides a significant strategic advantage for de-risking assets more quickly and cheaply.
Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.
China is poised to become the next leader in biotechnology due to a combination of structural advantages. Their regulatory environment is moving faster, they have a deep talent pool, and they can conduct clinical trials at a greater speed and volume than the U.S., giving them a significant edge.
The next decade in biotech will prioritize speed and cost, areas where Chinese companies excel. They rapidly and cheaply advance molecules to early clinical trials, attracting major pharma companies to acquire assets that they historically would have sourced from US biotechs. This is reshaping the global competitive landscape.
